Effects of recombinant platelet activating factor acetylhydrolase in obstructive jaundice.
OBJECTIVE
The aim of this study was to investigate effects of recombinant PAH (platelet activating factor acetylhydrolase), on tissue damage and on antioxidant response.


METHODS
A total of 30 Wistar-Albino type rats were used in this PAH treatment, and the subjects were divided into 3 groups namely sham, ligation and PAH treatment groups, each containing 10 rats. In PAH treatment and ligation groups, laparotomy was made; common bile duct was ligated and incised. Following ligation, blood and liver tissue were taken. In the sham group, the common bile duct was turned but no other procedure was applied. The subjects in the ligation group were given intraperitoneal placebo on the 2nd to 6th days; and those in the PAH treatment group were applied PAH at a 5-mg/kg dose. Blood and liver tissue were taken on postoperative day 7. The parameters examined in the blood sample included, liver function tests, superoxide dismutase, glutathione peroxidase, tumor necrosis factor-alpha and interleukin-6. In liver tissue, histopathologic examination was made.


RESULTS
Levels of AST, ALT, GGT, ALP, tumor necrosis factor-alpha and interleukin-6 were significantly higher than the levels in the sham group. These parameters, measured on the 7th day in the PAH treatment group were found to be significantly lower than the ligation group. Portal inflammation in the PAH given group was significantly lower than the ligation group.


CONCLUSIONS
Administration of PAH in experimental jaundice has produced improvement in liver functions, significant reductions in serum GGT and ALP, tumor necrosis factor-alpha and interleukin-6, and in liver damage whereas it has brought about an increase in the levels of antioxidant enzymes.
Kerek
Mustafa
M
Department of General Surgery, Erciyes University, Faculty of Medicine, Kayseri, Turkey. mkerek@ixir.com
Akyurek
Nusret
N
Sozuer
Erdogan M
EM
Arar
Makbule
M
Muhtaroglu
Sabahattin
S
D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase; D000818:Animals; D002779:Cholestasis / Q000188:drug therapy*; D005979:Glutathione Peroxidase / Q000097:blood; D015850:Interleukin-6 / Q000032:analysis; D008111:Liver Function Tests; D008297:Male; D010741:Phospholipases A / Q000627:therapeutic use*; D010972:Platelet Activating Factor; D051381:Rats; D017208:Rats, Wistar; D013482:Superoxide Dismutase / Q000097:blood; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
D015850:Interleukin-6; D010972:Platelet Activating Factor; D014409:Tumor Necrosis Factor-alpha; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase; D010741:Phospholipases A; D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase